Arkema : Good timing to anticipate the return of volatility
Entry price | Target | Stop-loss | Potential |
---|
€90.54 |
€98.7 |
€85 |
+9.01% |
---|
There has been very little movement in Arkema's share price. This situation is bound to change. An exit on the upside out of the current trading range should go with a comeback in volatility. Therefore, the timing for new long positions seems good.
Summary● The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths● With regards to fundamentals, the enterprise value to sales ratio is at 0.78 for the current period. Therefore, the company is undervalued.
● The company's share price in relation to its net book value makes it look relatively cheap.
● Given the positive cash flows generated by its business, the company's valuation level is an asset.
● The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses● As estimated by analysts, this group is among those businesses with the lowest growth prospects.
● The company's earnings growth outlook lacks momentum and is a weakness.
● The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.